IRIS
SORMANI, MARIA PIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 36.374
Totale 36.374
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 36.374
Totale 36.374
Salva come PNG Salva come JPEG
Città #
Genova 30.364
Rapallo 3.392
Genoa 2.514
Bordighera 104
Totale 36.374
Salva come PNG Salva come JPEG
Nome #
Ultrasound versus magnetic resonance imaging for Morton neuroma: systematic review and meta-analysis 155
A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosis. 150
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. 149
Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. 149
Can we measure long-term treatment effects in multiple sclerosis? 148
Indirect comparisons of treatment effects in multiple sclerosis. 146
Remote ischemic postconditioning as a strategy to reduce acute kidney injury during primary PCI: A post-hoc analysis of a randomized trial. 145
Modelling the distribution of cortical lesions in multiple sclerosis. 145
The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits. 144
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 144
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 144
Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies 143
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. 141
Defining the clinical course of multiple sclerosis: the 2013 revisions. 140
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. 140
Breast Density Assessment Using a 3T MRI System: Comparison among Different Sequences 140
Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. 139
Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: Interim report of a prospective comparative trial 139
Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. 138
Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. 137
Clinical epidemiology of ALS in Liguria, Italy. 136
Evaluation of insulin resistance in a cohort of HIV-infected youth. 136
Age-related changes in Conventional, Magnetization Transfer, and Diffusion-Tensor MR Imaging Findings: Study with Whole-Brain Tissue Histogram Analysis. 134
Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. 134
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 134
Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. 132
The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis 131
Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis 131
Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. 131
Changes in the normal-appearing brain tissue and cognitive impairment in multiple sclerosis 130
Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach 130
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 129
Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register 129
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 129
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment 127
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis - Establishing disease prognosis and monitoring patients 127
Treatment decisions in multiple sclerosis - insights from real-world observational studies. 127
Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. 127
The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis 126
Defining and scoring response to IFN-β in multiple sclerosis. 126
Laparoscopic splenectomy for hematologic diseases: a preliminary analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen (IRLSS). 126
Radiologically isolated syndrome: 5-year risk for an initial clinical event. 125
Different MRI patterns in MS worsening after stopping fingolimod 125
Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. 124
6 minute walk test in Duchenne MD patients with different mutations: 12 month changes. 124
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yes. 123
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach 123
Thirteen years of follow-up in patients with adjustable silicone gastric banding for obesity: weight loss and constant rate of late specific complications. 123
Optimizing therapy early in multiple sclerosis: An evidence-based view 123
Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis 123
Quantitative assessment of finger motor performance: Normative data 123
Statistical issues related to the use of MRI data in multiple sclerosis 122
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. 122
Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results 121
Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy 121
Scoring treatment response in patients with relapsing multiple sclerosis. 121
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis 121
Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study. 119
Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. 119
Laryngeal long-term morbidity after supraglottic laryngectomy and postoperative radiation therapy 118
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" 118
Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. 118
BCR-ABL nuclear entrapment kills human CML cells: ex-vivo study on 35 patients with the combination of Imatynib Mesylate and Leptomycin B 118
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. 118
Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain 118
Impairment in explicit visuomotor sequence learning is related to loss of microstructural integrity of the corpus callosum in multiple sclerosis patients with minimal disability. 118
Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging 117
Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. 117
The effect of Cladribine on T1 'black hole' changes in progressive MS 116
Incorporating domain knowledge into the fuzzy connectedness framework: application to brain lesion volume estimation in multiple sclerosis 116
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. 116
Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis 116
In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. 115
Long-term effect of rituximab in anti-mag polyneuropathy 115
Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study 115
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. 115
The most frequently asked question to a statistician: The sample size 115
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials 114
Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? 114
Time to first relapse as an endpoint in multiple sclerosis clinical trials. 114
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. 114
99mTc-white cell scanning to detect gut inflammation in children with inflammatory bowel diseases or spondyloarthropathies 113
THE EFFECT OF COPOLYMER 1 ON SERIAL GADOLINIUM-ENHANCED MRI IN RELAPSING REMITTING MULTIPLE SCLEROSIS. 113
Innovative quantitative testing of hand function in Charcot-Marie-Tooth neuropathy 113
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. 113
Clinical activity after fingolimod cessation: Disease reactivation or rebound? 113
Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. 112
The quality of reports of randomized trials in multiple sclerosis: a review. 112
Early neurodevelopmental assessment in Duchenne muscular dystrophy. 112
Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. 112
Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. 112
A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. 112
Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis 111
HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. 111
Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients 111
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis 111
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data 111
Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. 110
Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis 110
How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis? 110
Totale 12.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.903
article - articoli 102.471
book - libri 0
conference - conferenze 432
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 205.806
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.747 0 0 0 0 0 0 0 0 0 504 1.161 1.082
2019/202011.736 555 386 496 839 1.064 1.285 1.738 905 1.156 1.757 1.140 415
2020/20213.936 238 410 428 343 207 302 224 390 289 482 301 322
2021/20225.124 139 294 581 477 146 361 317 1.214 236 422 299 638
2022/20234.158 463 197 51 416 709 795 19 309 765 58 324 52
2023/20241.960 116 354 57 216 199 513 181 158 145 21 0 0
Totale 37.369